COPENHAGEN (Reuters) - Shares in Denmark's Novo Nordisk dropped 4.7 percent on Friday after a U.S. expert panel assessing the group's ultra long-acting insulin degludec said it will study the cardiovascular safety of the drug. The statement late on Thursday raised a potential obstacle to approval in the world's top market, sending Novo Nordisk's shares down 4.7 percent by 0700 GMT, against a 2.2 percent fall in the Copenhagen stock exchange's benchmark index. (Reporting by Copenhagen Newsroom) via Health News Headlines - Yahoo! News Read More Here..
No comments:
Post a Comment